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ABSTRACT
Objectives: The non-lactose fermenting Gram-negative bacilli (NLF-GNB) are notorious pathogens reportedly acquiring multiple drug resistance 
alarmingly and emerging as a public health threat globally. This study was conducted to isolate and identify these pathogens from clinical samples 
received routinely in our Bacteriology Laboratory and to analyze their antibiotic susceptibility patterns.
Methods: In this cross-sectional study, the first 100 NLF-GNB strains isolated consecutively from 1218 clinical samples were included through 
convenience sampling. The samples were processed using standard microbiological techniques.
Results: The most common isolate was Pseudomonas aeruginosa followed by Acinetobacter spp, Proteus spp, Shigella spp, Salmonella typhi, Providencia 
spp., and Morganella spp. P. aeruginosa and Acinetobacter spp. isolates were found to exhibit high susceptibility toward Colistin and Imipenem. 
Proteus spp. exhibited high sensitivity toward Imipenem, Aminoglycosides, Ceftazidime, and Cefepime. All Providencia isolates were susceptible to 
Amikacin, Cefepime, and Ceftriaxone. The only isolate of Morganella spp. was found to be susceptible to Amikacin, Cefepime, Ceftazidime, Piperacillin 
tazobactam, Ciprofloxacin, Imipenem, and Aztreonam. Shigella isolates exhibited very high susceptibility toward Imipenem followed by Gentamicin 
and Ceftazidime. All the isolates of S. typhi exhibited susceptibility toward Imipenem, Piperacillin tazobactam, Ceftazidime, Ceftriaxone, Cefoperazone 
sulbactam, and Chloramphenicol. 24% of test isolates were found to be Multidrug resistant.
Conclusion: Antimicrobial surveillance is needed to implement appropriate timely interventions to restrict the spread of multidrug-resistant clones. 
Strict infection prevention and control practices, with judicious antibiotic prescription policy, may help in tackling this problem by obviating the 
selection pressure.
Keywords: Non-lactose fermenting Gram-negative bacilli, Antimicrobial susceptibility, Antibiotic resistance, Samples, Isolates, Multidrug resistance.
INTRODUCTION
Aerobic non-fermenting Gram-negative bacilli (NFGNB) are a 
taxonomically diverse group of bacteria that are either not capable 
of utilizing carbohydrates as an energy source or degrading them via 
oxidative pathway [1-3].
NFGNB (Pseudomonas, Acinetobacter, Burkholderia, Stenotrophomonas, 
etc.) constitute about 15% of all clinical bacterial isolates. NFGNBs are 
emerging as important health-care-associated pathogens in the current 
scenario. Hospital strains are found to exhibit multidrug resistance (MDR). 
They have been incriminated in infections, such as septicemia, meningitis, 
pneumonia, urinary tract infections, and surgical site infections. NFGNBs 
are innately resistant to many antibiotics and are known to produce 
extended-spectrum ß-lactamases (ESBL) and Metallo ß-lactamases [4-6].
Apart from NFGNB, there is another group of non-lactose fermenters 
capable of utilizing glucose (Proteus, Salmonella, Shigella, Morganella, 
Providencia, etc.). These NLF-GNB are Notorious pathogens reportedly 
acquiring multiple drug resistance alarmingly and emerging as a public 
health threat.
MDR has been emerging rapidly and consistently in these groups of 
pathogens driven by selection pressure due to inappropriate irrational 
drug therapy. This has resulted in treatment failures leading to an 
extended hospital stay, health complications, and a significant rise in 
morbidity and mortality. The study of antibiotic susceptibility patterns 
of isolates is imperative in formulating a strategy for prompt and 
appropriate therapy and also plays a crucial role in the prevention and 
control of the disease. Continual consistent surveillance and monitoring 
of local antimicrobial resistance trends is a prerequisite for implementing 
rational measures and updating the therapeutic guidelines [4,6-8].
There are very few studies from India wherein the various NLF-GNBs, 
isolated from patients’ samples, have been identified and their clinical 
significance assessed. Hence, this cross-sectional study was undertaken 
to identify the various non-lactose fermenters isolated from the 
patients attending our hospital to assess their clinical significance and 
antimicrobial susceptibility pattern.
METHODS
This cross-sectional study was conducted in the Department of 
Microbiology, Government Medical College, Datia (MP), India, after 
obtaining clearance from Institutional Ethics Committee.
Study period and clinical samples
Samples such as blood, urine, sputum, wound swabs, pus, stool, other 
body fluids, ear swabs, throat swabs, and nasal swabs obtained from 
patients admitted or attending OPDs of various clinical departments in 
GMC, Datia, submitted to the Department of Microbiology for routine 
diagnostic workup.
Sample size
Through convenience sampling, first 100 non-lactose fermenting 
Gram-negative bacterial strains isolated consecutively from the clinical 
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samples processed as per the standard protocol in the duration 
between October 1, 2018, to April 30, 2020, whichever is earlier were 
included in the study.
The NLF-GNB isolates found to be contaminants or commensals 
concerning for the respective samples were excluded from the study. 
For e.g., Pseudomonas aeruginosa or Proteus spp. if isolated from stool 
culture were not included in the study, being a part of commensal flora 
of gastrointestinal tract.
Isolation and identification of bacterial isolates were done using 
standard microbiological techniques. The antimicrobial susceptibility 
test of all the test isolates was performed by the Kirby–Bauer Standard 
disc diffusion method and results were interpreted according to the 
CLSI 2018 guidelines [9-11].
RESULTS AND DISCUSSION
Through convenience sampling, first 100 non-lactose fermenting 
Gram-negative bacterial strains were isolated consecutively from 1218 
clinical samples, starting from October 1, 2018. The study target was 
achieved till January 31, 2020 (16 months).
The majority of samples yielding NLF-GNB test isolates belonged to the 
patients in the age group of 40–60 years (42%) followed by the patients 
in the age group of 20–39 years (34%).
Similar findings were observed in the study conducted by Grewal et al. 
2020, Benachinmardi et al. 2020, Reddy et al. 2019, Sajjad et al. 2017, 
and Bohra et al. 2017. However, Akbar et al. 2014 in a similar study 
conducted in Peshawar, Pakistan, found that most of the test isolates 
were contributed by the females and patients in the 11–30 years age 
group [1,8,12-14].
As evident in Fig. 1, more than half of the NLF test isolates were obtained 
from pus and urine. This finding is in concordance with other similar 
studies conducted by Reddy et al. 2019, Bhargava et al. 2015, Akbar et al. 
2014, Malini et al. 2009, and Grewal et al. 2020. But in the majority of 
studies conducted in the recent past, the test isolates were derived 
predominantly from pus and respiratory samples [1,7,12,15,16].
As evident in Fig. 2, the most common test organism isolated was 
P. aeruginosa followed by Acinetobacter spp. This finding is as per 
the similar studies by Upgade et al. 2012, Nautiyal et al. 2014, 
Gore and Pai 2015, Bhargava et al. 2015, Kamalraj et al. 2015, 
Mahajan et al. 2016, Sajjad et al. 2017, Gunasekar et al. 2018, Nazir et al. 
2019, Reddy et al. 2019, Benachinmardi et al. 2020, Grewal et al. 2020, 
and Juyal et al. 2020 [1,2,5,7,8,12,13,17-21].
But unlike our study, in few similar studies conducted by Sharma 
and Pant, 2017, Shah and Vaghela, 2018, and Paul and Borah, 
2020, Acinetobacter spp. was the most common isolate followed by 
P. aeruginosa [4,22,23].
Out of the 100 samples yielding the test isolates, polymicrobial growth 
was seen in 22 samples where the NLF-GNB were isolated along with 
other organisms. None of the samples yielded more than one NLF isolate.
The overall isolation rate of NLF isolates from the total 1218 clinical 
samples processed came out to be 8.2%. P. aeruginosa (4%) exhibited 
the highest isolation rate followed by Acinetobacter (2%). The sample-
wise and organism-wise isolation rates are depicted in Tables 1 and 2.
As evident in Table 3, P. aeruginosa was more common in pus, ear 
swabs, and urine contributing to 80% of its isolates, while less common 
in blood, body fluids, sputum, and throat swabs. This finding is in 
concordance with other similar studies conducted by Reddy et al. 2019, 


































Fig. 1: Sample wise distribution of NLF isolates
Table 1: Sample-wise isolation rate of test isolates
S. No. Specimens Number of 
samples
No. of NLF isolates % 
isolation
1. Pus 450 30 6.67
2. Urine 438 25 6
3. Blood 114 13 11.4
4. Stool 66 08 12
5. Sputum 56 04 7
6. Body fluids 46 04 9
7. Throat swab 28 01 3.6
8. Nasal Swab 20 01 5
Total 1218 100 8.2
Table 2: Organism-wise isolation rate of non lactose fermenting 
isolates
S. No. Organism No. of isolates % isolation 
1. Pseudomonas aeruginosa 50 4
2. Proteus mirabilis 10 0.8
3. Proteus vulgaris 05 0.4
4. Acinetobacter spp. 23 2
5. Salmonella typhi 03 0.25
6. Shigella sp 06 0.5
7. Providencia spp. 02 0.16
8. Morganella spp. 01 0.08
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In the present study, Acinetobacter spp. was found to be more common in 
pus, blood, and urine contributing to 83% of its isolates while less common 
in body fluids, sputum, ear swabs, and throat swabs. Similar findings 
were reported by Grewal et al. 2020, Reddy et al. 2019, and Kamalraj 
et al. 2015 [1,5,12] But in some studies by Malini et al. 2009, De Francesco 
et al. 2013, Benachinmardi et al. 2020, Sharma and Pant 2017, the organism 
was predominantly isolated from respiratory samples [4,8,16,24].
In the present study, most of the isolates of Proteus spp. (87%) were 
obtained from pus and urine like the other similar studies by Sharma 
and Pant, 2017, Wang et al. 2014, and Leulmi et al. 2014 [4,25,26] 
However, Bahashwan 2013 found that majority of Proteus spp. isolates 
were derived from sputum and wound swabs [27].
Out of three isolates of Salmonella typhi, two were obtained from stool 
culture and one from blood culture.
Shigella spp. being an enteropathogen, fecal specimens are the most 
preferred samples for culture. In our study too, all the six Shigella spp. 
isolates were obtained from stool culture as in the majority of similar 
studies [28-33].
Out of two isolates of Providencia spp., one each was isolated from urine 
and blood cultures. In the study period, we reported only one isolate of 
Morganella spp. from a urine sample.
In a study by Leulmi et al. 2014, Providencia spp. was mainly isolated 
from pus and urine cultures [26]. Liu et al. 2020, isolated Providencia 
spp. mainly from sputum and wound swabs [34].
In similar studies, Morganella spp. was predominantly isolated from 
pus, urine, and blood by Akbar et al. 2014, from pus and urine by Leulmi 
et al. 2014, and from urine by Sharma and Pant 2017 [4,15,26].
As evident in Fig. 3, the highest number of test isolates were obtained 
from clinical specimens from the ENT department followed by the 
Surgery, Pediatric, and Medicine departments. 60% of the NLF test 
isolates were obtained from IPD patients and 40% from OPD patients, 
while an opposite trend was seen in the samples from ENT department, 
wherein contribution from OPD patients (83%) far exceeded the IPD 
patients. On the other hand in the case of the Pediatric department, only 
2 out of 18 isolates were obtained from OPD samples, with Pediatric 
ICUs (PICU and SNCU) contributing more than 60% of the test isolates.
The antibiotic susceptibility pattern of NLF test isolates is depicted in 
Table 4. In our study, P. aeruginosa isolates were found to exhibit high 
susceptibility toward Colistin and Imipenem and very less susceptibility 
toward Ciprofloxacin, Aztreonam, and Co-trimoxazole. Similar 
findings were reported by Shah and Vaghela, Sharma and Pant, and 
Bhargava et al. [4,7,22].
Grewal et al. reported high resistance toward Aminoglycosides, 
Amoxycillin clavulanate, Fluoroquinolones, Aztreonam, and third and 
fourth generation Cephalosporins [1].
Kamalraj et al. reported high susceptibility toward Imipenem and 
high resistance toward third-generation Cephalosporins (3GC) 
and Ciprofloxacin. They reported 38.3% and 42.3% ESBL strains, 
respectively [5].
Kamalraj et al., Nagaveni et al., and Anuradha et al. reported 
11.6%, 24%, and 28 % of MBL producing strains of P. aeruginosa, 
respectively [5,35,36].
Malini et al. and Gore and Pai reported high susceptibility toward 
Imipenem, Ticarcillin, Amikacin, and Cefoperazone and least toward 
Co-trimoxazole [2,16].
Juyal et al. and Benachinmardi et al. reported high sensitivity toward 
Amikacin, Imipenem, Piperacillin tazobactam, and Ticarcillin 
clavulanate and least sensitivity toward Co-trimoxazole [6,8].
In our study, Acinetobacter spp. isolates were found to exhibit high 
susceptibility toward Colistin and Imipenem and very less susceptibility 
toward Ciprofloxacin, Cefepime, Ceftriaxone, Aztreonam, Amoxycillin 
clavulanate, Gentamycin, Tobramycin, and Co-trimoxazole.
Malini et al. reported high sensitivity toward Imipenem and Piperacillin 
and low susceptibility toward Ciprofloxacin, Co-trimoxazole, and third 
and fourth generation Cephalosporins [16]. Nautiyal et al. reported 
high sensitivity toward Imipenem and Piperacillin tazobactam and low 
sensitivity toward Aminoglycosides, Fluoroquinolones, 3GC, and Co-
trimoxazole [18].
Grewal et al. reported high sensitivity toward Imipenem and 
Cefoperazone sulbactam and low sensitivity toward Polymixin group, 
Ureidopenicillin group, Amoxycillin clavulanate, Aminoglycosides, 
Fluoroquinolones, Aztreonam, and third and fourth generation 
Cephalosporins [1].
Table 3: Sample-wise distribution of non-lactose fermenting isolates
S. No. Non-lactose fermenting Isolates Samples
Pus Urine Blood Stool Sputum Ear swab Body fluids Throat swab Nasal Swab Total
1. Pseudomonas aeruginosa 18 9 4 - 2 13 3 1 - 50
2. Proteus mirabilis 4 5 - - - 1 - - - 10
3. Proteus vulgaris 1 3 1 - - - - - - 05
4. Acinetobacter spp. 7 6 6 - 1 1 1 - 1 23
5. Salmonella typhi - - 1 2 - - - - - 03
6. Shigella spp. - - - 6 - - - - - 06
7. Providencia spp. - 1 1 - - - - - - 02
8. Morganella spp. - 1 - - - - - - - 01











































Fig. 3: Department-wise distribution of test isolates
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A very high level of resistance to different groups of antibiotics 
was reported by Benachinmardi et al., Juyal et al., Gupta et al., and 
Hodiwala et al., but the strains were comparatively susceptible to 
Imipenem [6,18,37,38].
Uma et al. 2009 and Anil et al. 2011 reported 70.9% and 21% of MBL 
producing strains of Acinetobacter baumannii, respectively [39,40]. 
Kamalraj et al. and Sinha et al. reported 25% and 28 % of ESBL strains, 
respectively [5,41].
A. baumannii is gaining more importance as a nosocomial notorious 
pathogen due to its potential to form a biofilm, which accounts for its 
outstanding antibiotic resistance and high virulence.
Proteus spp. in the present study exhibited high sensitivity towards 
Imipenem, Tobramycin, Amikacin, Gentamicin, Ceftazidime, and 
Cefepime and less sensitivity toward Cefoperazone sulbactam, 
Amoxycillin clavulanate, Piperacillin tazobactam, Ciprofloxacin, and Co-
trimoxazole.
Proteus mirabilis strains are generally found to be more susceptible 
to antimicrobials than Proteus vulgaris and other Proteus species. P. 
mirabilis has got intrinsic resistance to nitrofurantoin and tetracycline 
which could be used as an identification marker. However, it is generally 
susceptible to the Carbapenems, Penicillins, Aminoglycosides, and Co-
trimoxazole [42].
Bahashwan 2013 reported high sensitivity of Proteus spp. isolates 
toward Imipenem followed by Amikacin, Cefoxitin, Aztreonam, 
and Piperacillin. The other antibiotics (Amoxycillin clavulanate, 
Gentamicin, Ceftazidime, Ciprofloxacin, Cephalothin, Cefpiramide, and 
Co-trimoxazole) exhibited <40% sensitivity [27].
Feglo et al. 2010 reported very high levels of resistance in Proteus 
spp. isolates against Ampicillin, Co-trimoxazole, Tetracycline, and 
Chloramphenicol [43].
Mirzaei et al. reported high sensitivity in urinary isolates of P. mirabilis 
toward Amoxicillin-clavulanate, Carbapenems, 3GC, Aztreonam, 
Tobramycin, and Fluoroquinolones and low sensitivity toward 
Cotrimoxazole and Amoxicillin. They found all isolates exhibiting the 
capability of biofilm formation with 72% of strains being strong biofilm 
producers. 24% of isolates were sensitive to all antibiotics tested, while 
one isolate was pan resistant. 14.5% of the isolates were MDR strains 
and 10% were ESBL producers. Most of the ESBL producers were MDR 
strains [44].
Swenson et al. 1999 have shown that all P. vulgaris and Proteus penneri 
strains have got the capability of producing inducible β-lactamases 
which could hydrolyze primary and extended-spectrum penicillins 
and cephalosporins. This calls for the need for monitoring the drug 
susceptibility of Proteus isolates [45].
Since we have only one Morganella spp. and two Providencia spp. 
isolated in the present study, any statistically significant inference could 
not be drawn from the existing study data regarding antimicrobial 
resistance.
The only isolate of Morganella spp. was found to be susceptible to 
Amikacin, Cefepime, Ceftazidime, Piperacillin tazobactam, Ciprofloxacin, 
Imipenem, and Aztreonam and resistant to Gentamicin, Ceftriaxone, 
Cefoperazone sulbactam, Amoxycillin clavulanate, Trimethoprim-
sulfamethoxazole, Colisin, and Chloramphenicol.
All Providencia isolates were found to be susceptible toward Imipenem, 
Amikacin, Cefepime, and Ceftriaxone, while none toward Gentamycin, 
Amoxycillin clavulanate, Piperacillin tazobactam, Aztreonam, 
Chloramphenicol, and Tetracyclin.
Lieu et al. reported high susceptibility of Providencia stuarti isolates 
toward Imipenem, Fluoroquinolones, Amikacin, and Cefepime. All test 
isolates were resistant to Ampicillin sulbactam, Amoxicillin clavulanate, 
Ticarcillin clavulanate, Piperacillin tazobactam, Aztreonam, and 3GC. 
All 76 isolates were found to be ESBL producers out of which 92% 
exhibited multiple drug resistance [34].
In hospital settings, high levels of Ciprofloxacin resistance have been 
reported frequently for the Proteus and Providencia spp. isolates due 
to rampant usage of the same. Fass et al. 1995 reported decreasing 
susceptibility of P. stuartii to ciprofloxacin from 100% to 46% over a 
6 year period [46].
P. penneri is generally found to be more resistant to penicillins 
than P. vulgaris, and its susceptibility pattern resembles more with 
Morganella morganii than with other Proteus spp.
Table 4: Antibiotic susceptibility pattern of test isolates















1. Amikacin (30) 30 (60) 13 (86.67) 13 (56.5) 2 (66.7) 4 (66.7) 2 (100) 1
2. Gentamicin (10) 25 (50) 13 (86.67) 10 (43.5) 1 (33) 5 (83) 0 0
3. Cefepime (30) 30 (60) 12 (80) 9 (39) 2 (66.7) 2 (33) 2 (100) 1
4. Ceftazidime (30) 32 (64) 11 (73.3) 11 (48) 3 (100) 5 (83) 1 (50) 1
5. Ceftriaxone (30) 24 (48) 10 (66.67) 10 (43.5) 3 (100) 4 (66.7) 2 (100) 0
6. Cefoperazone 
sulbactum
23 (46) 6 (40) 11 (48) 3 (100) 5 (83) 1 (50) 0
7. Amoxycillin 
clavulanate
27 (54) 7 (46.67) 10 (43.5) 2 (66.7) 4 (66.7) 0 0
8. Piperacillin 
tazobactam
34 (68) 7 (46.67) 12 (52) 3 (100) 5 (83) 0 1
9. Ciprofloxacin (5) 23 (46) 7 (46.67) 7 (30) 2 (66.7) 5 (83) 1 (50) 1
10. Trimethoprim 
sulfamethoxazole
19 (38) 5 (33.3) 6 (26) 2 (66.7) 2 (33) 1 (50) 0
11. Imipenem (10) 42 (84) 15 (100) 19 (82.6) 3 (100) 6 (100) 1 (50) 1
12. Aztreonam 13 (26) - 3 (13) - - 0 1
13. Colistin 50 (100) - 22 (95.6) - - - 0
14. Chloramphenicol - 8 (53.3) - 3 (100) 3 (50) 0 0
15. Tetracyclin - - - - 2 (33) 0 -
16. Tobramycin 28 (56) 12 (80) 10 (43.5) - - 1 (50) -
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M. morganii and P. penneri are generally susceptible to cefoxitin, 
3GC,4GC, aztreonam, aminoglycosides, ciprofloxacin, and imipenem 
and resistant to cefazolin, 1GC, 2GC, Cefoperazone, amino, and 
ureidopenicillins.
Leulmi et al. reported high sensitivity of Proteus, Providencia, and 
Morganella spp. isolates toward cefoxitin, cefotaxime, imipenem, 
amikacin, and ciprofloxacin, and very little sensitivity toward 
amoxicillin, nalidixic acid, and Co-trimoxazole [26].
M. morganii and P. stuartii isolates also exhibited high resistance 
to ticarcillin, gentamicin, and chloramphenicol. More than 61% of 
isolates were Multidrug resistant strains (resistant to at least 3 groups 
of antibiotics). 15% of the isolates were ESBL producers with no 
significant difference among various species.
In the present study, Shigella spp. isolates exhibited very high 
susceptibility toward Imipenem followed by Gentamicin, Ceftazidime, 
Cefoperazone sulbactam, Piperacillin tazobactam, and Ciprofloxacin 
and very less susceptibility toward Cefepime and Co-trimoxazole.
While comparing the resistance patterns between two studies by 
Mamtha et al. in 2007 and 2012 in the same region, all Shigella isolates 
were found to be resistant to nalidixic acid and a marked increase in 
resistance was observed. Resistance to ciprofloxacin increased from 
30% to 87%, norfloxacin from 20% to 83%, ampicillin from 63% 
to 100%, tetracycline from 74% to 84%, and Co-trimoxazole from 
79% to 90%. However, there was a significant decrease in resistance 
against gentamicin and amikacin from 71% to 40% and 45% to 5%, 
respectively [32,47].
In both the studies, Shigella isolates exhibited high sensitivity toward 
3GC which is in accordance with our study. Similar findings were 
reported by Srinivasa et al. 2009 [31].
Shigellae may be susceptible to the aminoglycosides in vitro, but not in vivo 
due to poor penetration of the intestinal mucosa when given orally [48].
In addition to some fluoroquinolones, pivmecillinam (amdinocillin 
pivoxil) and ceftriaxone are the only antimicrobials found to be effective 
in the treatment of MDR strains of Shigella in all age groups. However, 
Azithromycin can be considered as an alternative drug among adults. 
However, these antibiotics should be used only when local strains are 
resistant to Ciprofloxacin [48].
Pazhani et al., in a study on childhood diarrhea (2001–2004), found 
that 50% of Shigella isolates were resistant to ampicillin and 96% 
to co-trimoxazole in 2001, which was reduced to 32% and 83%, in 
2002. While 83% of isolates were resistant to tetracycline and 56% to 
nalidixic acid in 2001 which increased to 89% and 62%, respectively, in 
2002. In addition, fluoroquinolone resistance emerged among Shigella 
dysenteriae and Shigella flexneri isolates in 2002 increased gradually 
during the study period from 11% to 25% [29].
We have isolated only three S. typhi isolates in our study which is not 
sufficient to give a clear generalizable picture of the local antimicrobial 
resistance pattern in the organism. However, all the isolates of 
S. typhi exhibited susceptibility toward Imipenem, Piperacillin 
tazobactam, Ceftazidime, Ceftriaxone, Cefoperazone sulbactam, and 
Chloramphenicol. High levels of resistance were observed toward 
Gentamicin.
Similar findings were reported by Mehta et al. 2018 Choudhary 
et al. 2013, Kumar et al. 2013, Singhal et al. 2014, and Gurung et al. 
2017 [49-53].
Mehta et al. 2018 and Gurung et al. 2017 reported MDR toward first-line 
drugs in more than 15 % of S. typhi strains which were also resistant to 
Nalidixic acid [49,53].
It is observed that many of the isolates resistant to Nalidixic acid (NARST) 
were found to exhibit in vitro susceptibility to fluoroquinolones. But 
as per CLSI guidelines, such strains (NARST) should be considered 
Fluoroquinolone resistant as Nalidixic acid is a surrogate marker to 
predict fluoroquinolone treatment failure.
The resistance against fluoroquinolones like Ciprofloxacin is following 
an increasing trend due to the selective pressure by its unrestricted 
injudicious usage in typhoid therapy. Nalidixic acid resistance among 
Salmonella spp. is rapidly increasing in India. However, the consistent 
use of Ciprofloxacin as the mainstay treatment of typhoid in NA resistant 
cases has led to a steady rise in MIC along with further mutations at the 
same locus which has resulted in the emergence of completely resistant 
strains.
Several studies in the recent past have shown a re-emergence of 
susceptibility of S. typhi toward the first-line antibiotics. This could 
be due to their inconsistent usage by clinicians over the last decade 
who are preferring newer antimicrobials over them resulting in the 
withdrawal of selection pressure.
In the present study, 24% of NLF-GNB test isolates were found to be 
Multidrug-resistant. In a hospital setting, Multidrug-resistant or pan-
resistant strains may transmit from one patient to another through 
the hands of health-care workers or via environmental contamination. 
These notorious pathogens are the potential reservoirs of resistance 
genes that could be transferred to other bacterial strains. The high levels 
of β-lactamase production and multidrug resistance of the isolates is 
an emerging public health threat globally. Environmental surveillance, 
searching for asymptomatically colonized persons through screening 
of patients as well as health-care workers, and using molecular 
epidemiology should be the requisite strategy for investigating the 
clusters of infection with pan-resistant organisms. These wild strains 
have great potential to survive in the hospital environment so improved 
antibiotic stewardship and infection control measures will be needed to 
inhibit the emergence and spread of multidrug-resistant NFGNB in the 
health-care setting [27,43,54].
In the current scenario due to rapidly emerging multiple drug resistance, 
the polymixins (polymyxin B and colistin) are being used frequently as 
the last line therapeutic option. However, the clinicians should restrict 
the use of the reserve drugs in exceptional conditions only [19].
CONCLUSION
The present study highlighted the fact that non-fermenter Gram-
negative bacilli like P. aeruginosa and Acinetobacter spp. along with 
the other non-lactose fermenter, GNBs like the Proteae family, S. typhi, 
and Shigella spp. had emerged as important pathogens causing serious 
infections in the community as well as hospital settings. Infections 
caused by these notorious pathogens are difficult to treat as they 
are rapidly acquiring resistance to the commonly used antibiotics. 
Ever-increasing problem of antibiotic resistance has been worsened 
by the slow pace of research regarding the development of newer 
antimicrobial molecules.
Antimicrobial surveillance is needed to implement appropriate timely 
interventions to restrict the spread of multidrug-resistant clones. Strict 
infection prevention and control practices, with judicious antibiotics 
prescription policy, may help in tackling the emerging threat of multiple 
drug-resistant bugs by obviating the selection pressure. Appropriate 
judicious selection and rotation/cycling of antibiotics guided by the 
knowledge of their susceptibility profiles is of utmost importance.
The implementation of an antibiotic policy at the hospital level for the 
control and restriction of injudicious antimicrobial use is imperative in 
managing nosocomial infections.
This is the need of the hour to develop therapeutic protocols guided 
by susceptibility profiles for tuning antibiotic therapy regimens 
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to minimize the dissemination of antibiotic-resistant pathogens. 
Furthermore, the isolation of infected or colonized patients is of 
paramount importance.
Global antimicrobial susceptibility surveillance systems should 
also focus on the prevalence of multidrug-resistant/pan-resistant 
organisms, rather than restricting to just resistance rates to individual 
antibiotics so that the global impact of this problem could be assessed.
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